Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
Taking safety, immunogenicity, and production capacity into account, the 3 μg doseof CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials….
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
-
Noosa News14 hours agoJust as Cannes Did, Sydney Film Festival Has Awarded Its Major 2025 Prize to Jafar Panahi’s ‘It Was Just an Accident’
-
Noosa News19 hours agoIranian Australians share ‘mixed’ emotions after Israeli missiles kill regime officials
-
Noosa News22 hours agoElderly hatchback driver killed in collision on Brisbane road
-
General18 hours agoAustralian cyclist Michael Matthews to miss Tour de France due to pulmonary embolism